MK-3682B: Additional Ph II C-CREST-1 and C-CREST-2 data

Data from 254 patients with chronic HCV infection with or without cirrhosis in Part B of the ongoing, open-label, international Phase II C-CREST-1 and C-CREST-2 trials showed that once-daily oral MK-3682B with or without ribavirin for

Read the full 360 word article

User Sign In